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COL4A2 is associated with lacunar
ischemic stroke and deep ICH
Meta-analyses among 21,500 cases and 40,600 controls
ABSTRACT
Objective: To determine whether common variants in familial cerebral small vessel disease (SVD)
genes confer risk of sporadic cerebral SVD.
Methods: We meta-analyzed genotype data from individuals of European ancestry to determine
associations of common single nucleotide polymorphisms (SNPs) in 6 familial cerebral SVD genes
(COL4A1, COL4A2, NOTCH3, HTRA1, TREX1, and CECR1) with intracerebral hemorrhage (ICH)
(deep, lobar, all; 1,878 cases, 2,830 controls) and ischemic stroke (IS) (lacunar, cardioembolic,
large vessel disease, all; 19,569 cases, 37,853 controls). We applied data quality filters and set
statistical significance thresholds accounting for linkage disequilibrium and multiple testing.
Results: A locus in COL4A2 was associated (significance threshold p , 3.5 3 1024) with both
lacunar IS (lead SNP rs9515201: odds ratio [OR] 1.17, 95% confidence interval [CI] 1.11–1.24,
p56.6231028) and deep ICH (lead SNP rs4771674: OR 1.28, 95%CI 1.13–1.44, p55.763
1025). A SNP in HTRA1 was associated (significance threshold p , 5.5 3 1024) with lacunar IS
(rs79043147: OR 1.23, 95% CI 1.10–1.37, p5 1.903 1024) and less robustly with deep ICH.
There was no clear evidence for association of common variants in eitherCOL4A2 or HTRA1with
non-SVD strokes or in any of the other genes with any stroke phenotype.
Conclusions: These results provide evidence of shared genetic determinants and suggest common
pathophysiologic mechanisms of distinct ischemic and hemorrhagic cerebral SVD stroke phenotypes,
offering new insights into the causal mechanisms of cerebral SVD. Neurology® 2017;89:1829–1839
GLOSSARY
CI 5 confidence interval; eQTL 5 expression quantitative trait loci; GWS 5 genome-wide association study; ICH 5 intrace-
rebral hemorrhage; ISGC 5 International Stroke Genetics Consortium; LD 5 linkage disequilibrium; OR 5 odds ratio; SVD 5
small vessel disease; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; WMH 5 white matter hyperintensities.
Small vessel diseases (SVDs) of the brain include a subtype that affects the small, deep, penetrat-
ing arteries and arterioles in the brain, hereafter referred to as deep cerebral SVD. This deep cere-
bral SVD is thought to be responsible for most symptomatic lacunar ischemic strokes and deep
intracerebral hemorrhages (ICHs), as well as for substantial cognitive and physical disabilities,
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and to be a major pathologic substrate for
brain MRI features, including white matter
hyperintensities (WMH) and brain micro-
bleeds.1,2 Increasing evidence supports a dis-
tinct vascular pathology for deep cerebral
SVD, but our knowledge of the underlying
genes and pathophysiologic mechanisms is
limited, and specific treatment strategies are
lacking.1
While the genetic determinants of com-
mon sporadic forms of cerebral SVD remain
largely unknown, mutations in at least 6
genes (COL4A1, COL4A2, HTRA1, CECR1,
NOTCH3, TREX1) are known to cause rare
familial forms of deep cerebral SVD.3,4 Such
genes may also contain variants conferring
risk for sporadic deep cerebral SVD. We pre-
viously investigated associations of common
variation in the COL4A1 and COL4A2 genes
with cerebrovascular phenotypes in a collabo-
rative meta-analysis, demonstrating an associ-
ation between an intronic COL4A2 locus and
sporadic deep ICH, and a suggestive association
with other deep cerebral SVD phenotypes
(lacunar ischemic stroke and WMH).5 The
same genetic locus has since been shown to
be associated withWMH at genome-wide asso-
ciation study (GWAS) levels of significance.6
We aimed to extend this promising candi-
date gene approach to assess associations of
common variants in all currently known famil-
ial deep cerebral SVD genes with stroke and its
subtypes, investigating the hypothesis that as-
sociations would be specific to the 2 key spo-
radic deep cerebral SVD stroke phenotypes,
lacunar ischemic stroke and deep ICH. We
were able to take advantage of the increased
sample sizes and more densely imputed geno-
type data now available through the Interna-
tional Stroke Genetics Consortium (ISGC)
(http://www.strokegenetics.org/) and associ-
ated collaborative groups.
METHODS Identification of participating studies. We
identified most currently available large GWASs of stroke and
stroke subtypes in individuals of European ancestry using a net-
work of collaborations associated with the ISGC.7–11 The entire
dataset comprised 20 case-control collections including 19,569
ischemic stroke cases and 37,853 controls, with information on
Trial of Org 10172 in Acute Stroke Treatment (TOAST) sub-
types (lacunar ischemic stroke, large vessel disease [LVD], car-
dioembolic),12 and 5 case-control collections including 1,878
ICH cases and 2,830 controls, with information on the main
ICH subtypes (table 1). For the majority of case collections,
population-matched controls were recruited from studies with
existing genotyping data (details of case-control collections found
in references 7–11).
Individual studies applied quality control measures before
providing the data. All data were imputed with the 1000 Ge-
nomes Phase 1 reference dataset (or to a merged reference panel
including the Genome of the Netherlands) using IMPUTE2 or
MACH software13 and provided with reference to Human
Genome reference build 19.
Data collection. We collected genotype summary statistics
from participating case-control collections for the COL4A1,
COL4A2, HTRA1, CECR1, NOTCH3, and TREX1 genes (en-
compassing all known familial deep cerebral SVD genes),
including a 10-kbp upstream and downstream flanking region for
each gene (table 2).
We focused on the lacunar ischemic stroke and deep ICH
phenotypes, but we also assessed LVD, cardioembolic and all
ischemic stroke for ischemic stroke case-control collections, and
lobar ICH and all ICH for ICH case-control collections to show
specificity of the association. For each of these phenotypes, we
collected summary data from each collection for all directly
genotyped or imputed SNPs in genes of interest: SNP reference
number and position, allele frequencies, association effect size
(b coefficient) and its standard error, association p value, and
imputation quality measure and value.
Data analysis. Setting the significance threshold. To allow
multiple testing while accounting for linkage disequilibrium
(LD) between SNPs, we calculated significance p values for each
gene using a modified version of the Nyholt method (MeffLi),
which controls accurately for error rate in evaluations of real and
simulated data.14–17 We used the 1000 Genomes CEU dataset18
SNP genotype information to calculate p values for 5 genomic
regions, treating the COL4A1 and COL4A2 genes as 1 region
because they are located in tandem on chromosome 13q34 and
share a promoter (table 2).
Pre–meta-analysis data filtering. We further filtered the
data to include only SNPs with the following attributes: (1)
imputation quality $0.3 from MACH, IMPUTE2, or
SNPTEST (because SNPs with very poor imputation quality
may yield unreliable associations); (2) minor allele frequency
$1% (because we were investigating common SNPs); (3) abso-
lute b value ,100,000 (because higher b values would generate
implausible odds ratios [ORs], suggesting unreliable associations);
and (4) biallelic SNPs (because the meta-analyses program could
not process multiallelic SNPs).
Meta-analyses of COL4A1, COL4A2, HTRA1, CECR1,
NOTCH3, and TREX1 SNPs for each phenotype. We meta-
analyzed genotype summary data from each contributing case-
control collection. We assessed associations of COL4A1,
COL4A2, HTRA1, CECR1, NOTCH3, and TREX1 SNPs with
each of the stroke phenotypes available, both those assumed to
represent deep cerebral SVD specifically (lacunar ischemic stroke,
deep ICH) and others (LVD ischemic stroke, cardioembolic
ischemic stroke, all ischemic stroke, lobar ICH, all ICH). Our
hypothesis was that associations would be specific to (or at least
strongest with) deep cerebral SVD phenotypes. We used
a fixed-effects inverse-variance–based model in METAL genetic
meta-analysis software, weighting the b coefficients by their
estimated standard errors and generating, for each SNP, the OR
per additional minor allele for being a case vs a control.19
Post–meta-analysis data filtering. After the meta-analyses,
we considered SNPs to be associated with the respective
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Table 1 Participating case-control collections
Ischemic stroke
Studies forming case-control collectionsa Cases, n Controls, n CE cases, n LVD cases, n SVD cases, n Mean age cases, y Mean age controls, y Genotyping panel
ASGC 1,162 1,244 240 421 310 73 70 Illumina 610
BRAINS 371 2,640 78 40 29 74 $65 Illumina 610
GASROS Illumina 296 377 106 68 24 67 48 Illumina
GASROS Affy 485 3,030 198 102 59 69 51 Affymetrix
GEOS 448 498 90 37 54 41 40 Illumina H Omni
HPS 588 571 — — — 65 59 Illumina 610
ISGS/SWISS 1,014 1,370 235 217 187 67 65 Illumina 550/610/660
Milano 366 407 64 73 25 57 51 Illumina 610/660
WHI 306 2,170 42 31 81 59 52 Illumina 1M
VISP 1,723 1,047 — — — 61 63 Illumina 5M
WTCCC2 Germany 1,174 797 346 330 106 67 63 Illumina 660
WTCCC2 UK 2,374 5,175 460 498 474 72 52b Illumina 660
BRAINS, ISGS, GASROS, SWISS, HABC 754 1,586 176 163 149 67 74 Illumina 650Q, 610, 1M
CIDR,c HRS, OAI 3,291 11,514 598 423 761 69 67 Illumina 5M, 2.5M, HumanOmni,
5Exome-4v1
Krakow 878 716 407 173 36 69 56 Illumina 5M
LSGS 459 453 157 75 55 67 56 Illumina 5M
BASICMAR, ADHD, INMA 868 1,218 408 184 276 75 — Illumina 5M, 1M
Graz 607 815 166 85 74 69 65 Illumina 610, 5M
SAHLSIS, LSR, MDC 1,579 1,362 223 150 183 62 61 Illumina 5M, 610
Interstroke 826 863 208 188 243 68 66 Illumina Human Exome Chip,
Cardiometabochip
Totald 19,569 37,853 4,202 3,258 3,126 —
Intracerebral hemorrhage
Case-control collectionsa Cases (n) Controls (n) Lobar ICHf cases (n) Deep ICHg cases (n) Mean age cases Mean age controls Genotyping panel
GOCHA 387 387 210 167 72 72 Illumina HumanHap 610 Quad
ISGC 528 530 181 313 72 66 Illumina HumanHap 610 Quad
GERFHS 628 573 258 370 68 67 Affymetrix 6.0
MDC 199 372 76 95 62 58 Human OmniExpress Exome
Bead Chip v 1.0
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phenotype if the relevant associations passed the relevant modi-
fied Nyholt-corrected p threshold, were based on data from
$50% of cases contributing to the analyses, and did not dem-
onstrate substantial heterogeneity (requiring I2 , 50% and p .
0.001 from x2 test).
We chose our filtering thresholds from those most commonly
used and accepted6–8,20 with the aim of ensuring that any associ-
ations deemed significant would be based on SNPs with suffi-
cient, reliable, and consistent data.
Further exploration of associated SNPs. When.1 SNP in
the same gene was associated with any given phenotype, we
used the 1000 Genomes project CEU population data to inves-
tigate the LD between the lead SNP (with the lowest p value) and
all other associated SNPs for the relevant gene-phenotype asso-
ciation. SNPs in moderate or strong LD (defined respectively as r2
and/or D9 $0.6 or $0.8) with the lead SNP were considered
likely to represent a signal from the same locus.21
We examined associations of all lead SNPs across all case-
control collections included in the respective meta-analyses and
of all lead SNPs with all other phenotypes, comparing findings
for deep cerebral SVD stroke phenotypes and non-SVD stroke
phenotypes.
Finally, we sought functional annotation data from the
Haploreg version 2 database (http://www.broadinstitute.org/
mammals/haploreg/haploreg.php),22 genotype-tissue expression
portal expression quantitative trait loci (eQTL) browser (http://
www.broadinstitute.org/gtex/), and the RegulomeDB database
(http://regulome.stanford.edu/) for all associated SNPs.
RESULTS Meta-analyses of COL4A1, COL4A2,
HTRA1, CECR1, NOTCH3, and TREX1 SNPs for each
phenotype. Modified Nyholt significance thresholds
for the 5 genomic regions are shown in table 2. Using
our preset data filtering criteria, we found associations
of 18 SNPs in COL4A2 with lacunar ischemic stroke,
9 SNPs in COL4A2 with deep ICH, and 1 SNP in
HTRA1 with lacunar ischemic stroke (table 3 and
figure 1). Two of the SNPs in the COL4A2 gene
(rs4771674 and rs9515199) were associated with
both lacunar ischemic stroke and deep ICH. There
were no associations of common SNPs in COL4A2 or
HTRA1 with any of the noncerebral SVD or com-
bined stroke phenotypes or of common variants in
COL4A1, CECR1, NOTCH3, or TREX1 with any of
the stroke phenotypes.
Further exploration of associated SNPs. LD between
COL4A2 SNPs. The lead SNPs were rs9515201 for
lacunar ischemic stroke (OR per additional A allele
1.17, 95% confidence interval [CI] 1.11–1.24, p 5
6.62 3 1028) and rs4771674 for deep ICH (OR
per additional A allele 1.28, 95% CI 1.13–1.44, p
5 5.763 1025). These 2 lead SNPs are in strong LD
with each other (r2 5 0.9/D9 5 1), suggesting that
this represents the same genetic signal.
We investigated the LD between the lead SNP
rs9515201 (most strongly associated SNP in the
locus) and all other associated SNPs in COL4A2.
Of the other 24 SNPs in COL4A2 associated with
lacunar ischemic stroke and/or deep ICH, 19 were in
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moderate to strong LD with the lead SNP, suggesting
that their signal may be from the same COL4A2
locus. The remaining 4 SNPs showed minimal LD
with the lead SNP, while data for 1 SNP were not
available, suggesting that there might possibly be
additional relevant loci (table e-1 at Neurology.org).
Associations across individual case-control collections in
the meta-analyses. The associations for COL4A2 SNPs
showed minimal to moderate heterogeneity across
individual case-control collections in the lacunar
ischemic stroke and deep ICH meta-analyses (I2 5
0%–49%, heterogeneity p 5 0.7–0.01; and I2 5
0%–42%, heterogeneity p 5 0.1–0.5 respectively),
while the associations across individual collections for
rs79043147 inHTRA1 in the lacunar ischemic stroke
meta-analysis showed only minimal heterogeneity
(I2 5 4%, heterogeneity p 5 0.41), suggesting con-
sistent results (figure e-1). All imputed SNPs showed
a good imputation quality of .0.7.
Associations with other phenotypes of the lead COL4A2
SNPs. Figure 2 shows association results for the lead
COL4A2 SNPs (rs9515201 and rs4771674) associ-
ated with lacunar ischemic stroke and deep ICH
across all 7 phenotypes assessed. Although
rs9515201 was associated only with lacunar ischemic
stroke (OR 1.17, 95% CI 1.11–1.24, p 5 6.62 3
1028), there was a suggestive association of similar
magnitude with deep ICH (OR 1.21, 95% CI
1.07–1.37, p 5 2.15 3 1023). Rs4771674 was asso-
ciated with both cerebral SVD phenotypes: lacunar
ischemic stroke (OR 1.14, 95% CI 1.07–2.10, p 5
1.63 1025) and deep ICH (OR 1.28, 95% CI 1.13–
1.44, p 5 5.76 3 1025).
There were no associations with non-SVD stroke
or combined SVD and non-SVD phenotypes. ORs
for the all ischemic stroke and all ICH phenotypes
were intermediate between those for SVD and those
for non-SVD phenotypes, suggesting that associa-
tions with these combined phenotypes were driven
by results for lacunar ischemic stroke and deep
ICH.
Associations with other cerebrovascular phenotypes of the
HTRA1 SNP. Rs79043147 was associated only with
lacunar ischemic stroke (OR 1.23, 95% CI 1.10–
1.37, p5 1.903 1024) but also showed a suggestive
association with deep ICH (OR 1.56, 95% CI 1.24–
1.97, p5 1.713 1024) (figure 2). In fact, the p value
for deep ICH passed the significance threshold, but
the SNP did not pass our preset heterogeneity filter
and was therefore not considered associated overall.
There were no associations with non-SVD stroke or
combined SVD and non-SVD phenotypes.
Functional annotation. All COL4A2 and HTRA1
SNPs associated with lacunar ischemic stroke or deep
ICH were intronic. The GTEx eQTL browser search
revealed no significant eQTLs for any of these SNPs.
However, the RegulomeDB database revealed that 2
COL4A2 SNPs were in an area likely to affect bind-
ing, 2 COL4A2 SNP were in an area less likely to
affect binding, and 17 COL4A2 SNP showed minimal
binding evidence, suggesting that these SNPs are
located in areas of the genome that may have regula-
tory functions (table e-2).
DISCUSSION Our results demonstrate an associa-
tion of an intronic, possibly regulatory locus in
COL4A2 with 2 distinct deep cerebral SVD pheno-
types, lacunar ischemic stroke and deep ICH.We also
found an association of deep cerebral SVD with
HTRA1, demonstrating an association with lacunar
ischemic stroke and a suggestive association with deep
ICH. Finding the same genetic signal associated with
both ischemic and hemorrhagic sporadic stroke
confirms the usefulness of a joint exploration of
cerebrovascular phenotypes and the potential for
genetic studies to shed light on common underlying
mechanisms.
Our findings for COL4A2 are supported by pre-
vious work showing the relevance of this genomic
region in sporadic deep cerebral SVD. A sequence
analysis of COL4A1/COL4A2 found missense muta-
tions in sporadic ICH cases.23,24 In addition, our
Table 2 Six genes assessed: Location, number of SNPs, and Nyholt association p values regarded as
significant
Gene/genomic region Chromosome Coordinatesa
SNPs
Nyholt p valuenall neff
COL4A1/COL4A2 13 110,791,310–111,175,373 2,555 147 3.5 3 1024
HTRA1 10 124,211,041–124,284,424 417 93 5.5 3 1024
CECR1 22 17,650,192–17,712,738 422 97 5.3 3 1024
NOTCH3 19 15,260,444–15,321,792 278 72 7.1 3 1024
TREX1 3 48,491,186–48,519,044 60 38 1.3 3 1023
Abbreviation: SNP 5 single nucleotide polymorphism.
aBased on the Human Genome reference build 19.
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Table 3 All associated SNPs passing post–meta-analysis filters
SNP Minor allele Major allele
Minor allele
frequency OR (95% CI)a Association p value Direction of effectb Cases, %c I2
Heterogeneity
p value
Lacunar ischemic stroke:
COL4A2 (Nyholt significance
p threshold 3.5 3 1024)
rs9515201 A C 0.31 1.17 (1.11–1.24) 6.62 3 1028 111111121111111221 100 48 0.01
rs4771674 A G 0.39 1.14 (1.07–1.2) 1.60 3 1025 111111121121?11221 92 49 0.01
rs113696651 T C 0.02 1.61 (1.29–2.01) 2.25 3 1025 1122111?211111?111 98 29 0.13
rs9521729 A G 0.31 0.88 (0.83–0.94) 5.42 3 1025 222212222122?11222 92 11 0.32
rs9515199 C T 0.39 1.13 (1.06–1.19) 5.47 3 1025 111111121121?11221 92 39 0.05
rs9559771 G A 0.12 0.84 (0.77–0.91) 6.56 3 1025 222212222222222222 100 20 0.21
rs7319311 G A 0.32 0.88 (0.83–0.94) 7.48 3 1025 222212222222?11222 92 0 0.45
rs4502089 C T 0.27 0.88 (0.83–0.94) 7.49 3 1025 22222212222122211122 100 17 0.25
rs9521768 T G 0.27 1.13 (1.06–1.21) 9.09 3 1025 111121121211211111 100 34 0.08
rs67472641 Dd Rd 0.37 1.16 (1.08–1.26) 9.86 3 1025 ?????11211111????? 57 24 0.24
rs9521770 G A 0.27 1.13 (1.06–1.2) 1.21 3 1024 111121121211211111 100 33 0.08
rs9583488 A G 0.32 0.89 (0.83–0.94) 1.21 3 1024 222212222222?11122 92 10 0.34
rs11619583 C T 0.46 1.12 (1.06–1.18) 1.23 3 1024 111112111111121111 100 36 0.06
rs7320755 C G 0.32 0.89 (0.84–0.94) 1.53 3 1024 222212222222?01122 86 8 0.36
rs77104783 A C 0.08 0.8 (0.71–0.9) 1.78 3 1024 222221222122?22222 92 0 0.66
rs9515198 T C 0.28 0.89 (0.83–0.94) 2.00 3 1024 222212222122?11122 92 13 0.30
rs7140030 A G 0.25 1.12 (1.06–1.2) 2.36 3 1024 111111111121112121 100 36 0.06
rs9588148 T G 0.21 0.88 (0.83–0.94) 3.19 3 1024 222222222222211222 100 3 0.41
Deep ICH: COL4A2 (Nyholt
significance p threshold
3.5 3 1024)
rs4771674 A G 0.4 1.28 (1.13–1.44) 5.76 3 1025 21111 100 27 0.24
rs9521733 C T 0.4 1.27 (1.13–1.42) 8.10 3 1025 11112 100 0 0.48
rs9521735 C G 0.41 1.27 (1.13–1.43) 8.91 3 1025 11112 100 0 0.51
rs9515200 C G 0.39 1.27 (1.13–1.43) 9.36 3 1025 11112 100 26 0.25
rs9521732 A C 0.41 1.26 (1.12–1.42) 9.89 3 1025 11112 100 0 0.45
rs9521734 T A 0.4 1.26 (1.12–1.42) 1.01 3 1024 11112 100 0 0.52
rs1999013 G A 0.41 1.27 (1.12–1.43) 1.07 3 1024 21112 100 38 0.17
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previous meta-analyses in a smaller, partly overlap-
ping sample already demonstrated an association of
this COL4A2 locus with deep ICH and a suggestive
association with other cerebral SVD phenotypes.5 By
increasing the sample size (by 40% for lacunar ische-
mic stroke and by 15% for deep ICH) and density of
coverage in the present study, we have now estab-
lished a substantial association of the same locus with
lacunar ischemic stroke and confirmed the association
with deep ICH. Furthermore, a recently published
GWAS identified our lead SNP for lacunar ischemic
stroke to be associated with another deep cerebral
SVD phenotype, WMH.6
While the association with COL4A2 is supported
by previous data and a convincing signal for both
ischemic and hemorrhagic phenotypes, the associa-
tion with HTRA1 is suggestive but less certain. On
the basis of our p threshold, the HTRA1 SNP was
associated with both lacunar ischemic stroke and deep
ICH, but there was significant heterogeneity in the
deep ICH meta-analyses. We are also aware of a pre-
vious report suggesting an association of rare variation
in HTRA1 with more extreme sporadic deep cerebral
SVD phenotypes.25 Thus, this finding should be pur-
sued in independent, large samples to replicate the
association.
From a biological point of view, our strategy of
investigating these familial genes jointly is supported
by an emerging view that the resulting familial deep
cerebral SVDs have similar disease mechanisms
involving disruption of the cerebrovascular matri-
some. Familial mutations leading to alterations of ma-
trisome proteins and function could be a convergent
pathway driving the functional and structural altera-
tions of small brain vessels and disease manifestations,
and similar mechanisms could play a role in sporadic
disease.26
COL4A1 and COL4A2 genes encode the collagen
protein chains, a major component of the vascular
basement membrane.27 Their dominant missense
mutations are associated with basement membrane
defects and endoplasmic reticulum stress and cause
rare familial SVDs.23,28–30 Recent data suggest that
manipulation of endoplasmic reticulum stress (e.g.,
with 4-phenyl butyric acid) is a potential therapeutic
option for collagen IV diseases, including hemor-
rhagic stroke.28 Mutations in HTRA1 gene are asso-
ciated with cerebral autosomal recessive arteriopathy
with subcortical infarcts and leukoencephalopathy.31
While the majority of HTRA1 mutations cause this
autosomal recessive cerebral SVD, heterozygous
HTRA1mutations associated with cerebral SVD have
also recently been reported.32 HTRA1 encodes the
HTRA1 enzyme, which, through regulating trans-
forming growth factor-b signaling, plays an impor-
tant role in the formation of blood vessels.
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Possible reasons for an apparent lack of an associ-
ation with COL4A1, CECR1,NOTCH3, and TREX1
include a genuine lack of association in our study
population; weaker association not detected because
of sample size; suboptimal diagnosis of SVD pheno-
types in the original studies, resulting in reduced
power; and variability in the density and quality of
genotyping across different genes. In addition, we
used a 10-kbp flanking region to cover regulatory
areas for all genes; therefore, relatively more conser-
vative p values may have been derived for smaller
genes (TREX1) after adjustment for the number of
Figure 1 COL4A2 regional association plots for (A) lacunar ischemic stroke, (B) deep ICH, and (C) HTRA1
regional association plot for lacunar ischemic stroke
Only SNPs passing the post–meta-analysis filters (heterogeneity I2 , 50%, p . 0.001, $50% cases contributing data) are
displayed. Red dashed lines mark the relevant Nyholt significance p thresholds. Dots mark individual SNPs with respect to their
chromosomal position (x-axis) and p value for association between each SNP and phenotype (left y-axis). The SNP in purple is the
most strongly associated (lead) SNP; linkage disequilibriumwith this lead SNP determines the colors for other SNPs, as seen from
the r2 color coding on figure. Recombination rates (right y-axis), shown by the continuous blue lines, are measured as frequency of
exchange per unit physical distance (centimorgan [cM]/mega base pair [Mb]). ICH 5 intracerebral hemorrhage; SNP 5 single
nucleotide polymorphism.
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Figure 2 Associations of COL4A2 and HTRA1 SNPs across all phenotypes
Diamonds represent pooled ORs across all case-control collections for each phenotype, with the line through the diamond showing its 95%CI. Associations
significant at relevant Nyholt threshold are shown in red; nonsignificant associations with SVD phenotypes are shown in black; and nonsignificant associ-
ations with non-SVD phenotypes are shown in gray. CE 5 cardioembolic; CI 5 confidence interval; ICH 5 intracerebral hemorrhage; IS 5 ischemic stroke;
LVD 5 large vessel disease; OR 5 odds ratio; SNP 5 single nucleotide polymorphism.
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SNPs tested. In addition, because we treated the
COL4A1/COL4A2 region as one, more conservative
p values were derived for the COL4A1 gene than if we
had treated it as a separate region.
Our study has several strengths. We investigated
a specific, prespecified hypothesis, clearly defining the
phenotypes and candidate genes of interest on the basis
of preexisting supporting data. Through a network of
collaborative groups, we could include the majority
of currently available data from stroke genetics studies
of individuals of European ancestry. We used appro-
priate methods to correct for multiple testing.
There were some limitations. First, while we have
shown that SNPs in COL4A2 are associated with
lacunar ischemic stroke and deep ICH through ana-
lyzing data for the specific candidate region, the asso-
ciations did not reach GWAS significance (p # 5 3
1028), most likely because of limited sample size.
However, the lead lacunar ischemic stroke SNP
(rs9515201) had a value of p 5 6.6 3 1028, and it
has been shown that a substantial proportion of SNPs
with a p value in this “borderline”GWAS significance
range (p . 5 3 1028 and p # 1 3 1027) represent
genuine, replicable associations.33 Second, we did not
adjust the statistical threshold for the number of
genomic regions and phenotypes investigated, consid-
ering this overly conservative because we were inves-
tigating a series of specific related hypotheses rather
than a single hypothesis. However, had we further
adjusted the COL4A1/COL4A2 region p value for
the number of tests (3.5 3 1024/25 5 1.4 3
1025), the association for the lead SNP with lacunar
ischemic stroke would have remained significant.
Third, our analyses found a locus in COL4A2 con-
taining several SNPs associated with deep cerebral
SVD, most (but not all) of which were in moderate
to strong LD with the lead SNP. This suggests that
the association was likely driven by the lead SNP, but
the possibility remains that independently significant
signals in the locus may emerge.34 Further investiga-
tion of this would require additional analyses adjusted
for the lead SNP, requiring genome-wide genetic data
that were not sought for this study, given its targeted
hypothesis-driven approach. Fourth, the diagnostic
workup leading to TOAST subtype classification
was study specific, which may introduce some het-
erogeneity. Fifth, not all studies controlled for age in
their statistical analyses before inclusion in the meta-
analyses, and this may decrease the study power.
Finally, we were not able to include data for addi-
tional relevant phenotypes such as WMH and brain
microbleeds in the present study.
While genetic studies of ischemic stroke and ICH
have generally been pursued separately, these findings
emphasize the mechanistic insights that can be gained
from joint analyses of cerebrovascular phenotypes. We
have shown that the same genetic signal is associated
with clinically evident sporadic ischemic and hemor-
rhagic stroke, but the joint exploration approach is fur-
ther supported by previous GWASs showing a locus
on chromosome 1q22 to be associated with both deep
ICH and WMH.10,35 In addition, it has recently been
shown that a locus on chromosome 6p25, near the
FOXF2 gene (also associated with familial deep SVD),
is associated with all stroke (likely driven by SVD stroke
phenotypes) and suggestively with WMH.36
Follow-up studies should further explore potential
common genetic signals for deep cerebrovascular
ischemic and hemorrhagic SVD phenotypes in larger
sample sizes and for additional relevant phenotypes
such as WMH and brain microbleeds and should
include non-European ethnic groups. Future studies
could also assess the potential contribution of rare
variants to common cerebral SVD phenotypes in
these mendelian genes. In addition, the robust find-
ings for COL4A2 now merit further deep sequencing
of the entire genomic region among sporadic deep
cerebral SVD cases, with detailed functional studies
of promising variants thus identified.
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